Astellas
About
Astellas is a global life sciences company headquartered in Tokyo, and its Cambridge site places it in the Kendall Square biotech community. The company aims to turn innovative science into value for patients, with marketed therapies in oncology, ophthalmology, urology, immunology and women’s health. It operates in more than 70 countries and areas with more than 14,000 employees, and it focuses its research on diseases with high unmet medical need.
Astellas celebrated its 20th anniversary in April 2025. It reinvests a large share of revenue, about 14.7 percent of sales, into research and development, and it partners with outside organizations around the world. Current work includes cell therapy research that combines people, AI and robotics, and the company uses digital tools across its operations. Its Corporate Strategic Plan 2026 sets its direction and priorities for the next five years.
What to Know
- Global revenue in fiscal 2025 was about $14.17 billion.
- The company publishes an integrated report covering its strategy and social impact.
- It supports patient advocacy in rare diseases such as X-linked myotubular myopathy.
- A board of directors and a top management team lead the company.
- Astellas is a member of the Kendall Square Association.
Is this your business?
Claim it to add hours, photos, a description and a spotlight story.